Author + information
Background: Residual cardiovascular risk remains high among statin-treated patients. Complementary diet therapy could contribute to increase cardiovascular protection and would be preferable to add-on prescriptions. Bioactive compounds such as omega 3 fatty acids, plant sterols and polyphenols have been shown to reduce inflammation, dyslipidemia and oxidative stress. Therefore, our aim was to evaluate the effects of omega 3 fatty acids, plant sterols and polyphenols on atherosclerosis risk biomarkers of patients submitted to stable doses of statins.
Methods: A randomized crossover clinical study was carried out on 53 subjects. At each visit, participants received either a bioactive or a control treatment. Bioactive treatment consisted of fish oil softgels, chocolate that contained plant sterols and green tea. Control treatment consisted of soy oil softgels, regular chocolate and anise tea. Plasma lipids and high-sensitivity C-reactive protein (hs-CRP) were assessed by commercial kits. Plasma sterols and malondialdehyde (MDA) were quantified by chromatography (GC-MS and HPLC).
Results: After 6 weeks of intervention, bioactive treatment reduced plasma LDL-C (-13.7%±3.7, p=0.002) and hs-CRP (-35.5%±5.9, p=0.027). Plasma triacylglycerol (-15.68% ± 5.94, p=0.02) and MDA (-40.98% ± 6.74, p=0.04) were reduced in subgroups of patients (n=23) with baseline values above the median (93 mg/dL and 2.23 umol/L, respectively). Analysis of lathosterol and campesterol in plasma suggested that intensity of LDL-C reduction was influenced by cholesterol absorption rate rather than its endogenous synthesis. Patients that presented a higher sterol absorption rate at baseline showed higher LDL-C reduction than those who presented the opposite profile.
Conclusions: The combined bioactive therapy proved to be a simple and low cost strategy to reduced inflammation, dyslipidemia and oxidative stress. The intensity of this beneficial effect depends on baseline values and on the sterol synthesizer/absorber profile of the patients.
Poster Hall, Hall C
Friday, March 17, 2017, 10:00 a.m.-10:45 a.m.
Session Title: Advances in Cholesterol Measurement and Management
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1106-051
- 2017 American College of Cardiology Foundation